Cléa Percier

Global Scientific Director
Novo Nordisk Health Care AG, Zürich, Switzerland
Zürich, Zurich, Switzerland

Presentation(s):

• PB0231 - Treatment satisfaction and joint health outcomes within a real-world haemophilia B population: the Adelphi Disease Specific Programme™ survey

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• PB0503 - Clinical outcomes of people with hemophilia B treated with N9-GP in real-world settings: the Adelphi Disease Specific Programme™ hemophilia study

  Monday, June 24, 2024
  13:45 – 14:45 ICT